echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > In 2020, the global antibody drug market will exceed $150 billion, and the five major target "cornucopia" will be released

    In 2020, the global antibody drug market will exceed $150 billion, and the five major target "cornucopia" will be released

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In the past two months, following the disclosure of the financial reports of various pharmaceutical giants, the annual global sales of best-selling drugs ushered in the most comprehensive inventory.
    The global drug market exceeds 900 billion U.
    S.
    dollars, and antibody drugs account for 150 billion U.
    S.
    dollars in sales.
    After the development boom of antibody drug targets, the world's most profitable antibody target in 2020 is still TNFα, and Roche has returned to the top 1 global drug sales company with 9 TNFα antibodies.
    However, looking at the domestic antibody market alone, the potential of TNFα antibodies has yet to be developed, and the sales leader is PD-1/PD-L1.

    The global antibody market has exceeded 150 billion U.
    S.
    dollars, and sales of multiple products have exceeded one billion

    The global antibody market has exceeded 150 billion U.
    S.
    dollars, and sales of multiple products have exceeded one billion

    According to the latest financial report data of pharmaceutical companies, the global antibody drug market will reach a new high in 2020, reaching 155 billion U.
    S.
    dollars, thanks to the sales contribution of at least 80 antibody drugs.
    Among them, Humira (adalimumab) will be global in 2020.
    Sales of 19.
    96 billion US dollars, continue to dominate the list.
    Merck’s PD-1 antibody Keytruda (pembrolizumab) sales reached US$14.
    38 billion, Johnson & Johnson/Tanabe Mitsubishi’s Stelara (usnumab) sales reached US$7.
    951 billion, ranking second and third respectively .

    Bamlanivimab and REGEN-COV, which debuted in the 2020 earnings report, performed well.
    Due to the spread of the global new crown epidemic, Eli Lilly's new crown neutralizing antibody Bamlanivimab and regenerating cocktail antibody REGEN-COV were authorized by the FDA for emergency use in November 2020 for the treatment of patients with new crown.
    According to financial data, Eli Lilly’s Bamlanivimab will have global sales of US$871 million in 2020, and REGEN-COV of Regenerant will also have US$186 million in revenue in 2020.

    Table 1: Antibody drugs with global sales of over 100 million U.
    S.
    dollars

    Note: The exchange rate is converted into 1 Euro = 1.
    1413 US dollars, 1 Danish kroner = 0.
    1531 US dollars, 1 Swiss franc = 1.
    066 US dollars, 1 Japanese yen = 0.
    0094 US dollars, 1 British pound = 1.
    2836 US dollars; Takeda, Ono Pharmaceutical, Daiichi San Pharmaceutical, Kyowa Kirin The 2020 financial reports of Co.
    , Ltd.
    , Eisai and Alexion have not been disclosed at present, and the corresponding sales are calculated based on 2019, the same below.

    Five major targets "cornucopia" totaled 91 billion U.
    S.
    dollars, and heavy target antibodies helped Roche reach the top

    Five major targets "cornucopia" totaled 91 billion U.
    S.
    dollars, and heavy target antibodies helped Roche reach the top

    At present, a large number of popular targets are closely watched by pharmaceutical companies.
    The PD-1/PD-L1 targets in the past two years are typical examples.
    In addition, for VEGF, TNFα, EGFR, HER2, CD20, CGRP/CGRPR, The research and development of PCSK9, CDK4/6, etc.
    is also extremely hot, and many pharmaceutical companies have invested a lot of manpower, material and financial resources in the development of related target antibodies.
    Commercial value is one of the important indicators for evaluating the overall value of drugs, especially for antibody drugs.

    According to the statistics of antibody drugs in the financial reports of major pharmaceutical companies, the top five sales targets of antibody drugs in 2020 are: TNFα, PD-1/PD-L1, VEGF/VEGFR, HER2 and CD20, the top five targets The scale of the antibody market of Dian reaches 91 billion U.
    S.
    dollars, accounting for more than half of the global antibody market, which can be called a "target cornucopia".
    Among them, a total of 8 TNFα target antibodies are counted.
    With the blessing of Xiu Mei Le, the TNFα antibody market has reached 31.
    382 billion US dollars.

    Figure 1: The proportion of antibody sales in the world's top ten targets

    Among the world's top ten target antibodies, 9 companies with 3 or more varieties include Roche, Amgen, Johnson & Johnson, Novartis, Tanabe Mitsubishi, Merck, Eli Lilly, Pfizer, Daiichi Sankyo, etc.

    Roche widened the gap with the second-ranked company by a large proportion.
    9 blockbuster target antibody drugs include 3 CD20 target antibodies, 3 HER2 target antibodies, 2 VEGF/VEGFR target antibodies, 1 PD-1/PD-L1 target antibody.
    The new "three carriages" Perjeta, Tecentriq, Kadcyla and the old "three carriages" Avastin, MabThera/Rituxan, and Herceptin overlapped, driving Roche's performance strongly and successfully helping the company to become the world's TOP1 enterprise in 2020.

    Figure 2: Companies with 3 or more target varieties in the top ten sales

    The five major target antibody domestic wars are raging, and the target king translocates

    The five major target antibody domestic wars are raging, and the target king translocates

    In foreign countries, Xiu Mei Le successfully held its position as the world's drug king for the eighth consecutive year, and helped the entire TNFα target to stay on top of antibody drugs.
    However, looking back at the domestic antibody market, the TNFα target has no global arrogance.
    Compared with the top five other targets in the global antibody market, the TNFα target 2020H1 is the bottom of the terminal sales of public medical institutions in China, which is several hundred million yuan.
    The sales volume lost to PD-1/PD-L1, VEGF/VEGFR, HER2 and CD20.
    Having said that, both adalimumab and infliximab have been included in the medical insurance catalog at the end of 2019, and they are likely to become the driving force for the increase of TNFα antibodies.
    In the second half of 2020, the terminal sales of TNFα antibodies in public medical institutions in China will usher in a substantial increase The rise.

    In China, the target PD-1/PD-L1 is another style.
    Among the top five other targets in the global antibody market, the target PD-1/PD-L1 ranked first in the terminal sales of public medical institutions in China in the first half of 2020, with a sales amount exceeding 3 billion yuan.
    PD-1/PD-L1 indications are aimed at a variety of tumor types, and its clinical effects have shown its extraordinary strength.
    Although the 8 major PD-1/PD-L1 that have been on the market in China are fiercely competitive, they have a strong impact on PD-1/PD-L1.
    The overall market position of L1 has little effect.

    Figure 3: Sales of the five major targets in 2020H1 in China's public medical institutions

    Source: Mi Nei.
    com, China's urban public medical institutions terminal competition pattern

    Source: Mi Nei.
    com, China's urban public medical institutions terminal competition pattern

    to sum up

    to sum up

    The antibody drug market is currently the largest category in the global biopharmaceutical market.
    It has met the previously unmet clinical needs with its great clinical value, and has also proved its great commercial value with its excellent market performance.
    The sales of some antibody drugs and antibody targets are closely related to factors such as national policies, scope of indications, product prices, corporate promotion methods, the strength of competitors, and even the sudden new crown epidemic.
    It is understandable that all profitable companies are A strong leader.

    The steadily increasing sales figures brought about by commercial value also promotes R&D companies to conduct more in-depth research on popular targets.
    Only the persistent research on innovation and unpopular targets will usher in year after year in financial reporting.
    New faces appearing in.
    Traveling against the current, if you do not advance, you will retreat.
    The situation of antibody targets is completely different at home and abroad, which is a vigilance for domestic companies and also a business opportunity.

    Source: Corporate financial reports, Mynet’s multinational listed company sales database, Mynet’s global drug R&D database

    Original title: In 2020, the global antibody drug market will exceed $150 billion, and the five major target "cornucopia" will be released.
    Does the domestic PD-1/PD-L1 turn over the TNFα car?

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.